Skip to main content

Candel Therapeutics, Inc 8-K, filed Nov 12, 2026

Candel Therapeutics, Inc. (CADL)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 13, 2026

About this 8-K

Candel Therapeutics, Inc filed this 8-K on November 12, 2026.

On November 12, 2026, Candel Therapeutics, Inc. entered a new at-the-market agreement with Jefferies LLC for up to $50,000,000 of common stock, after selling approximately $50,000,000 under its 2025 agreement. Jefferies receives a 3.0% commission on gross proceeds. AI summary

Items reported

  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits